Abstract
-
▴ Degarelix is a gonadotropin-releasing hormone (GnRH) receptor antagonist that, in common with GnRH receptor agonists (e.g. leuprolide, goserelin and triptorelin), is indicated for use as an androgen-deprivation therapy in patients with advanced prostate cancer.
-
▴ In 1-year, randomized, open-label, phase II or III trials in patients with all stages of prostate cancer, subcutaneous degarelix was associated with rapid, profound and sustained suppression of serum testosterone and prostate-specific antigen (PSA), without evidence of testosterone surges or microsurges.
-
▴ In the phase III trial, degarelix (240 mg initially followed by 80 mg every 28 days) was considered to be effective and noninferior to intramuscular leuprolide (7.5 mg every 28 days) with regard to inducing and maintaining suppression of serum testosterone to castrate levels (i.e. ≤0.5 ng/mL).
-
▴ Degarelix induced testosterone suppression more rapidly than leuprolide. Median serum testosterone levels of ≤0.5 ng/mL were achieved by day 3 in degarelix recipients, but not until day 28 in leuprolide recipients.
-
▴ PSA suppression was also more rapid with degarelix than with leuprolide, with significant between-group differences in serum PSA levels favouring degarelix at 14 and 28 days.
-
▴ Degarelix treatment for 1 year was generally well tolerated; the adverse events reported were mostly related to subcutaneous drug administration (i.e. injection-site reactions) and hormonal androgen deprivation (e.g. hot flushes).
Similar content being viewed by others
References
National Institute for Health and Clinical Excellence. Prostate cancer: diagnosis and treatment. NICE clinical guideline 58 [online]. Available from URL: http://www.nice.org.uk/Guidance/CG58/Guidance/pdf/English [Accessed 2009 Sep 2]
Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007 Mar; 18(3): 581–92
American Cancer Society. Cancer facts & figures 2009. Atlanta: American Cancer Society; 2009 [online]. Available from URL: http://www.cancer.org/downloads/STT/500809web.pdf [Accessed 2009 Jul 21]
Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007 Jun; 177(6): 2106–31
Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007 Apr 20; 25(12): 1596–605
Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2008 Jan; 53(1): 68–80
Cook T, Sheridan WP. Development of GnRH antagonists for prostate cancer: new approaches to treatment. Oncologist 2000; 5(2): 162–8
Perlmutter MA, Lepor H. Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol 2007; 9 Suppl. 1: S3–8
Anderson J, Abrahamsson PA, Crawford D, et al. Management of advanced prostate cancer: can we improve on androgen deprivation therapy? BJU Int 2008 Jun; 101(12): 1497–501
van Poppel H, Nilsson S. Testosterone surge: rationale for gonadotropin-releasing hormone blockers? Urology 2008; 71(6): 1001–6
Conn PM, Crowley WFJ. Gonadotropin-releasing hormone and its analogues. N Engl J Med 1991 Jan 10; 324(2): 93–103
Lepor H. Comparison of single-agent androgen suppression for advanced prostate cancer. Rev Urol 2005; 7 Suppl. 5: S3–12
Huirne JAF, Lambalk CB. Gonadotropin-releasing-hormone-receptor antagonists. Lancet 2001 Nov 24; 358(9295): 1793–803
Doehn C, Sommerauer M, Jocham D. Drug evaluation: degarelix — a potential new therapy for prostate cancer. IDrugs 2006; 9(8): 565–72
Broqua P, Riviere PJ, Conn PM, et al. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix. J Pharmacol Exp Ther 2002 Apr; 301(1): 95–102
Tornoe CW, Agerso H, Nielsen HA, et al. Pharmaco-kinetic/pharmacodynamic modelling of GnRH antagonist degarelix: a comparison of the non-linear mixed-effects programs NONMEM and NLME. J Pharmacokinet Pharmacodyn 2004 Dec; 31(6): 441–61
Princivalle M, Broqua P, White R, et al. Rapid suppression of plasma testosterone levels and tumor growth in the Dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist. J Pharmacol Exp Ther 2007; 320(3): 1113–8
Balchen T, Agerso H, Wu F, et al. Single subcutaneous administration of a novel, fast-acting gonadotropin-releasing hormone antagonist degarelix (FE200486) with depot characteristics in healthy men [abstract no. PO-288]. Clin Exp Pharmacol Physiol 2004 Aug; 31 Suppl. 1: 126
Van Poppel H, Tombal B, de la Rosette JJ, et al. Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker-results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol 2008 Oct; 54(4): 805–15
Gittelman M, Pommerville PJ, Persson B-E, et al. A 1-year, open-label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J Urol 2008 Nov; 180(5): 1986–92
Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008 Dec; 102(11): 1531–8
Tornoe CW, Agerso H, Nielsen HA, et al. Population pharmacokinetic modeling of a subcutaneous depot for GnRH antagonist degarelix. Pharm Res 2004 Apr; 21(4): 574–84
Degarelix for injection: US prescribing information. Parsippany (NJ): Ferring Pharmaceuticals, Inc., 2008 Dec
FIRMAGON 120mg injection. Summary of product characteristics. Slough: Ferring Pharmaceuticals Ltd, 2009 Feb 2
European Medicines Agency. Assessment report for Firmagon. International Nonpropriety Name: degarelix (as acetate). Procedure no. EMEA/H/C/000986 [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/firmagon/H-986-en6.pdf [Accessed 2009 Jul 20]
US Food and Drug Administration. Center for Drug Evaluation and Research. Application number: 22-201. Clinical pharmacology and biopharmaceutics review(s) [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022201s000_ClinPharmR.pdf [Accessed 2009 Aug 21]
Klotz L, Boccon-Gibod L, Shore ND, et al. Degarelix in a 12-month randomized, open-label, parallel-group phase III study in prostate cancer patients [late-breaking abstract plus poster]. 103rd Annual Meeting of the American Urological Association; 2008 May 17-22; Orlando (FL)
US Food and Drug Administration. FDA approves drug for patients with advanced prostate cancer [online]. Available from URL: http://www.fda.gov/bbs/topics/NEWS/2008/NEW01935.html [Accessed 2009 Jan 5]
Ferring Pharmaceuticals. European Commission grants Ferring Pharmaceuticals approval of Firmagon® (degarelix) for treatment of prostate cancer [online]. Available from URL: http://www.ferring.com [Accessed 2009 Mar 6]
Acknowledgements and Disclosures
The manuscript was reviewed by: H. Isbarn, Martiniclinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany; H. Suzuki, Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan.
The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Frampton, J.E., Lyseng-Williamson, K.A. Degarelix. Drugs 69, 1967–1976 (2009). https://doi.org/10.2165/10484080-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/10484080-000000000-00000